- $3.25bn
- $2.94bn
- $460.16m
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows
Brief: Zai Lab Receives U.S. FDA Fast Track Designation For Zocilurtatug Pelitecan (Zoci)
Zai Lab HK shares fall to 5-week low on weak Q1 results
Brief: Zai Lab Announces Global Clinical Trial Collaboration And Supply Agreement To Evaluate Novel Dll3 Adc, Zocilurtatug Pelitecan, In Combination With A Bispecific T-Cell Engager Therapy
Zai Lab rises as it teams up with Amgen for lung cancer drug trial
Brief: Zai Lab Announces National Medical Products Administration (Nmpa) Approval Of Augtyro™
Brief: Zai Lab Announces Dosing Of First Participant In Global Phase 1/1b Study Of ZL-1503, An IL-13/IL-31R Bispecific Antibody For Treatment Of Atopic Dermatitis
Brief: Zai Lab Updates On Amgen's Bemarituzumab Phase 1B/3 Fortitude-102 Study
Brief: Zai Lab Unveils Promising Phase 1 Data for DLL3 ADC; Launches Global Phase 3 Trial
Brief: Zai Lab Announces Second Quarter 2025 Financial Results And Recent Corporate Updates
Zai Lab Ltd expected to post a loss of 4 cents a share - Earnings Preview
Brief: Zai Lab Announces Positive Topline Phase 3 Results For Bemarituzumab In Fibroblast Growth Factor Receptor 2B (FGFR2b) Positive First-Line Gastric Cancer
Brief: Zai Lab Presents Positive Phase 1 Data For Zl-1310, A Dll3-Targeted Adc
Brief: Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung Cancer
Brief: Zai Lab Complies With HFCAA
Zai Lab Ltd expected to post a loss of 5 cents a share - Earnings Preview